TABLE 2

Changes in plaque size and host cell morphology with sublethal antibiotic doses

Host bacteriaPhagePhenotypea
APCTXKMTETCPFXMitCSMXTMP
Gram positive
    S. aureusSA11+ S++ S+ S+ S+++ S+ S
    E. faecalisPBEF7+++ S+++ S+b+ S++ S+b+ S
PBEF9+++ S+++ S+b+ S++ S+ S
    B. cereusPBBC03+ F+++ F+ F+ F+++ F+++ F
Gram negative
    E. coli K-12T4++ F+ F++ F++ F++ F++b
    E. coli CrooksPBEC22++ F++ F+ F++ F++ F+b+ Fb
PBEC24++ F++ F+b++ F+++ F++ F++b+ F
PBEC82+++ F++ F++ F+++ F++ F+ Fb
    P. aeruginosaPA26++ F++ F+b+ F++b++b++ F
PA22++ F++ F+b− Fb++b++b+b++ F
PA25+ F+++ F+b+ F++b+++b+b++ F
  • a AP, ampicillin; CTX, cefotaxime; KM, kanamycin; TET, tetracycline; CPFX, ciprofloxacin; MitC, mitomycin C; TMP, trimethoprim; SMX, sulfamethoxazole; S, swelling; F, filamentation; +, >30% increase in plaque diameters; ++, >60% increase in plaque diameters; +++, >90% increase in plaque diameters; −, no change.

  • b Phage production increased in the absence of a bacterial morphological change.